Floatz logo

Ponsegromab

Anorexia

Pfizermonoclonal_antibodyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Anorexia cohort.

Asset / SponsorPhaseRating
MEGESTROL ACETATE IMPURITY B
Alliance for Clinical Trials in Oncology
Phase 3BB
1-235-TUMOR NECROSIS FACTOR RECEPTOR (HUMAN) FUSION PROTEIN WITH 236-467-IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN FC FRAGMENT), DIMER
Mayo Clinic
Phase 3BB
Docetaxel
Alliance for Clinical Trials in Oncology
Phase 3B
Infliximab
Alliance for Clinical Trials in Oncology
Phase 3B
Olanzapine
Alliance for Clinical Trials in Oncology
Phase 3B

View all 12 →

Same molecule, other indications

Ponsegromab is also rated in:

CachexiaDormant
BB
Indicative ·
69 / 100
View asset →
nutritional disorderDormant
BB
Indicative ·
64 / 100
View asset →
pancreatic ductal adenocarcinomaDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →